Auriga acquires license to market Aquoral spray

Auriga commented that Xerostomia could represent a potential marketplace estimated at more than $1 billion. The current size of the prescription marketplace for xerostomia medications is at approximately $54 million.

Xerostomia, characterized by dry mouth, affects millions of people worldwide. It can be caused by autoimmune diseases and is a problematic side-effect of more than 400 prescription medications, such as antidepressants. Aquoral is an FDA-cleared, patented prescription mouth spray device that treats xerostomia

Auriga acquired the Aquoral license from Laboratories Carilene, a France-based therapeutics developer, and is contingent upon three payments worth $1.5 million with a supply agreement that includes a 5% royalty return.

“Acquiring the license for Aquoral is the latest achievement in our strategic business plan to build a substantial portfolio of revenue generating products,” said Philip Pesin, CEO of Auriga.

The company expects to launch the Aquoral product by the first quarter of 2007.